Recombinant factor VIIa: Its background, development and clinical use

Current Opinion in Hematology

Volumn 14, Issue 3, 2007, Pages 225-229

  Hedner, Ulla ^a,b,c  

^a LUND UNIVERSITY   (Sweden)

^b NOVO NORDISK A S   (Denmark)

^c NONE   (Sweden)

Author keywords

Factor VIIa; Hemophilia; Hemostasis

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN;

ABSENCE OF SIDE EFFECTS; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMATOMA; CLINICAL TRIAL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; FIBRIN CLOT; FIBRINOLYSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; NONHUMAN; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN DEGRADATION; REVIEW; SINGLE DRUG DOSE; THROMBOCYTE ACTIVATION; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

FACTOR VII; HEMOPHILIA A; HEMORRHAGE; HEMOSTASIS; HUMANS; RECOMBINANT PROTEINS; THROMBIN;

EID: 34247145483     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3280dce57b     Document Type: Review

References (23)

1. Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol 2006; 124:747-757. Most recent overview of the development of rFVIIa. Includes many references.
2. Hedner U, Kisiel W. The use of human factor VIIa in the treatment of two hemophilia patients with high-titer inhibitors. J Clin Invest 1983; 71:1836-1841.
3. Blajchman MA, Vamvakas EC. The continuing risk of transfusion-transmitted infections. New Engl J Med 2006; 355:1303-1305. Recent report on the risk of transfusion of blood products.
4. Brinkhous KM, Hedner U, Garris JB, et al. Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. Proc Natl Acad Sci U S A 1989; 86:1382-1386.
5. Diness V. rFVIIa in an endotoxin model and in a Wessler model. Proceedings of 2nd Symposium on New Aspects of Hemophilia Treatment; January 1991; Copenhagen, Denmark. Bussum, The Netherlands: Medicon Europe; 1991. pp. 147-150.
6. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80:912-918.
7. Kavakli K, Makris M, Zulfikar B, et al. Home treatment of haemarthroses using a single dose regimen of recombinant activated FVII in patients with haemophilia and inhibitors. J Thromb Haemost 2006; 4:367-371. Report on the use of a high dose of rFVIIa.
8. Hedner U, Erhardtsen E. Potential role of recombinant factor VIIa as a hemostatic agent. Clin Adv Hematol Oncol 2003; 1:112-119.
9. Konkle B, Friedrich U, Abrams Z. Secondary prophylactic treatment with rFVIIa in patients with haemophilia A or B and inhibitors with high requirements for on-demand treatment. Poster presentation at the World Fed Haemophila, Vancouver, Canada, May 2006. Haemophilia 2006; 12:363. Abstract 14 PO. First report on the prophylactic effect of rFVIIa in hemophilia.
10. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Art Thromb Vasc Biol 2002; 22:1381-1389.
11. Rapaport SI, Rao LV. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 1992; 12:1111-1121.
12. Walsh PN. Platelet coagulation-protein interactions. Semin Thromb Haemost 2004; 30:461-471.
13. Monroe DM, Hoffman M, Olivier JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99:642-647.
14. Lisman T, Mosnier LO, Lambert T, et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe haemophilia A. Blood 2002; 99:175-179.
15. Lisman T, de Groot PG, Lambert T, et al. Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A. J Thromb Haemost 2003; 1:2175-2178.
16. Allen GA, Persson E, Campbell RA, et al. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol 2007; 4 January [Epub ahead of print]. Report on an increased effect of a modified FVII molecule.
17. Lisman T, Adelmeijer J, Cauwenberghs S, et al. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. J Thromb Haemost 2005; 3:742-751.
18. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352:777-785.
19. Fridberg MJ, Hedner U, Roberts HR, Erhardtsen E. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coag Fibrinol 2005; 16:259-266.
20. Friederich PW, Levi M, Bauer KA, et al. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation 2001; 103:2555-2559.
21. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2:899-909.
22. Roberts HR, Monroe DM, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004; 41 (suppl 1):101-108.
23. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295:293-298. Review of reported adverse events (Medwatch) by the US Food and Drugs Association.